Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 1-Year Low – Here’s Why

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report)’s stock price hit a new 52-week low on Tuesday. The stock traded as low as $27.10 and last traded at $27.57, with a volume of 356,063 shares trading hands. The stock had previously closed at $28.01.

Analysts Set New Price Targets

Several research firms have weighed in on IONS. Wall Street Zen raised Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. The Goldman Sachs Group cut their price target on Ionis Pharmaceuticals from $58.00 to $41.00 and set a “neutral” rating for the company in a report on Tuesday, November 10th. Morgan Stanley reduced their price objective on shares of Ionis Pharmaceuticals from $104.00 to $75.00 and set an “overweight” rating for the company in a research note on Tuesday, November 10th. Royal Bank Of Canada lowered their price objective on Ionis Pharmaceuticals from $85.00 to $60.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 10th. Finally, Raymond James Financial reissued an “outperform” rating and set a $54.00 price objective on shares of Ionis Pharmaceuticals in a research note on Monday, November 9th. Nineteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.71.

Get Our Latest Stock Analysis on Ionis Pharmaceuticals

Ionis Pharmaceuticals Stock Performance

The company has a current ratio of 5.43, a quick ratio of 7.73 and a debt-to-equity ratio of 3.42. The business has a fifty day moving average of $43.05 and a 200-day moving average of $64.30. The company has a market cap of $4.49 billion, a PE ratio of -8.15 and a beta of 0.43.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative net margin of 56.98% and a negative return on equity of 120.62%. The company had revenue of $242.72 million during the quarter, compared to the consensus estimate of $178.17 million. During the same period in the prior year, the firm earned ($0.80) earnings per share. Ionis Pharmaceuticals’s revenue was up 54.8% on a year-over-year basis. Equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.57 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Shannon L. Devers sold 1,357 shares of Ionis Pharmaceuticals stock in a transaction on Friday, October 16th. The stock was sold at an average price of $43.54, for a total value of $59,083.78. Following the completion of the sale, the executive vice president owned 17,811 shares of the company’s stock, valued at $775,490.94. The trade was a 7.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael R. Hayden purchased 5,000 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, November 10th. The shares were acquired at an average cost of $29.64 per share, with a total value of $148,200.00. Following the transaction, the director directly owned 27,000 shares in the company, valued at approximately $800,280. The trade was a 22.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.81% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Aquatic Capital Management LLC lifted its stake in Ionis Pharmaceuticals by 39.9% in the 3rd quarter. Aquatic Capital Management LLC now owns 59,561 shares of the company’s stock worth $2,659,000 after purchasing an additional 16,980 shares in the last quarter. Worldquant Millennium Advisors LLC lifted its position in shares of Ionis Pharmaceuticals by 48.2% in the third quarter. Worldquant Millennium Advisors LLC now owns 72,585 shares of the company’s stock worth $3,241,000 after buying an additional 23,609 shares in the last quarter. Great Point Partners LLC purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter worth about $18,753,000. Entropy Technologies LP boosted its stake in Ionis Pharmaceuticals by 36.6% during the third quarter. Entropy Technologies LP now owns 50,303 shares of the company’s stock valued at $2,246,000 after buying an additional 13,488 shares during the last quarter. Finally, Jump Financial LLC boosted its stake in Ionis Pharmaceuticals by 54.0% during the third quarter. Jump Financial LLC now owns 471,682 shares of the company’s stock valued at $21,061,000 after buying an additional 165,352 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

Read More

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.